Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT01130272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

807

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: Eluxadoline
DRUG: Placebo

Sponsor

Furiex Pharmaceuticals, Inc